The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
GLP-1 receptor agonists are increasingly used for weight loss, potentially benefiting patients needing joint replacement. However, concerns remain regarding surgical safety and long-term effects on bone and muscle health, necessitating further research and careful patient management.
Millie Bobby Brown responded to fan speculation that Vecna's slimmer appearance in Stranger Things season 5 was due to Ozempic. She also revealed how she discovered the show's finale before the official table read.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Aisling McCarthy, after years of struggling with her weight, has successfully lost 100lbs. Her transformation involved weight loss medication prescribed by her doctor, coupled with counseling, leading to a newfound sense of food freedom and improved well-being.
A clinical trial is underway to test a GLP-1 based weight loss treatment for overweight cats. The implant, releasing medication over six months, aims to improve insulin sensitivity and energy metabolism. Results are expected next summer.
New research indicates that an oral version of a well-known weight loss medication delivers similar results to its injectable counterpart. However, healthcare professionals emphasize that its intended use should be as a treatment for chronic conditions, rather than a superficial fix.
Letters to the editor address various pressing issues. Topics range from the implications of widespread GLP-1 drug use to concerns about educational costs and gun laws.
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
